Kasra Shakeri‐Nejad

Author

Kasra Shakeri‐Nejad

Novartis (Switzerland)

Also Known As

K Shakeri-Nejad, Kasra Shakeri-Nejad, Kasra Shakeri‐Nejad

Publications

468

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research Novartis (India)Novartis (United States)

About

Kasra Shakeri‐Nejad is an author at Novartis (Switzerland) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	199
2	Pharmacology	3	3	199
3	Health Sciences	1	1	172
4	Hepatology	1	1	172
5	Pathology	1	1	172

Kasra Shakeri‐Nejad

Publications

342

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment Joachim Stangier, Hildegard Stähle, Karin Rathgen, The Journal of Clinical Pharmacology Dabigatran EtexilatePathologyModerate Hepatic ImpairmentPharmacotherapyThrombosis	2008	172
Impact of siponimod on vaccination response in a randomized, placebo-controlled study Mike Ufer, Kasra Shakeri‐Nejad, Anne Gardin, Neurology Neuroimmunology & Neuroinflammation	2017	36
<scp>AQW</scp>051, a novel, potent and selective<scp>α</scp>7 nicotinic<scp>ACh</scp>receptor partial agonist: pharmacological characterization and phase<scp>I</scp>evaluation Dominik Feuerbach, Nicole Pezous, Kasra Shakeri‐Nejad, British Journal of Pharmacology	2014	32
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects Anne Gardin, Mike Ufer, Eric Legangneux, Clinical Pharmacokinetics	2018	28
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi, International Journal of Clinical Pharmacology and Therapeutics	2016	14
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects Anne Gardin, Cathy Gray, Srikanth Neelakantham, European Journal of Clinical Pharmacology Molecular PharmacologyHealthy SubjectsSiponimod PharmacokineticsPharmacologyCyp2c9/3a4 Inducer	2018	14
Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi, Clinical Therapeutics Heart FailureCardiac RepolarizationCardiovascular DiseaseHealthy SubjectsMedicine	2015	13
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study Anne Gardin, Angela Dodman, Sampath Kalluri, International Journal of Clinical Pharmacology and Therapeutics	2016	13
Elucidation of the Metabolic Pathways and the Resulting Multiple Metabolites of Almorexant, a Dual Orexin Receptor Antagonist, in Humans Jasper Dingemanse, Petra Hoever, Matthias Hoch, Drug Metabolism and Disposition	2013	10
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes Anne Gardin, Kasra Shakeri‐Nejad, Andrea Feller, European Journal of Clinical Pharmacology	2019	10

Page 1